On Friday, Shares of General Electric Company (NYSE:GE), lost -2.38% to $24.59.
General Electric Company declared that it has accomplished the formerly declared sale of its U.S. Sponsor Finance business and a bank loan portfolio, representing aggregate ending net investment (ENI) of about $10 billion, to Canada Pension Plan Investment Board (CPPIB) in a transaction valued at more than $11 billion.
As formerly declared, GE is embarking on a strategy to focus on its high-value industrial businesses and is selling most GE Capital assets. GE and its Board of Directors have determined that current market conditions are favorable to pursue disposition of these assets. GE will retain the financing “verticals” that relate to GE’s industrial businesses.
The Sponsor Finance transaction closes at a valuation consistent with signing and, as predictable, releases about $2.5 billion of capital. GE Capital believes it is on track to deliver about $35 billion of dividends to GE under this plan, as formerly declared (subject to regulatory approval). Changes in the transaction size were driven by normal portfolio seasonality and pay-off in the bank loan portfolio during the sign to close period.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment.
Shares of American Airlines Group Inc. (NASDAQ:AAL), declined -5.31% to $39.75, during its last trading session. The firm has dropped 6.49% during the last 3-month period. Year-to-Date the stock performance stands at -25.4%. The company shares have rallied 0.84% in the past 52 Weeks. On January 26, 2015, the shares registered one year high of $56.2 and one-year low was seen on October 13, 2014 at $28.1. The 50-day moving average is $41.52 and the 200-day moving average is recorded at $45.76. S&P 500 has rallied 1.35% during the last 52-weeks.
American Airlines and Cuba Travel Services plan to operate the first charter flights between Los Angeles International Airport (LAX) and Jose Marti International Airport (HAV) in Havana later this year, providing travelers the only nonstop service connecting the West Coast to Cuba since travel restrictions were eased.
“American is the premier carrier in Los Angeles and throughout the Caribbean, and this new charter flight shows how we continue to expand our reach by offering new routes and services our customers want,” said Art Torno, American’s senior vice president – International and Cargo. “We stand ready to offer planned service as soon as the United States and Cuba allow commercial flights.”
“We are excited to expand our partnership with American to comprise flights from Los Angeles to Havana,” said Michael Zuccato, General Manager at Cuba Travel Services. “We will continue to deliver a high quality travel experience and opening up new West Coast access to Cuba will bring a convenient, affordable option to authorized travelers.”
American’s new charter service between Los Angeles and Havana will be sold by Cuba Travel Services and will operate on Saturdays starting Dec.12 with Boeing 737 aircraft. In addition, American will operate a Saturday flight between Miami International Airport and Havana, also sold by Cuba Travel Services.
American Airlines Group Inc., through its auxiliaries, operates in the airline industry. As of December 31, 2014, the company operated 983 mainline jets, in addition to 566 regional aircrafts through regional airline auxiliaries and third-party regional carriers. It serves 339 destinations in 54 countries.
Finally, Boston Scientific Corporation (NYSE:BSX), ended its last trade with -3.08% loss, and closed at $16.35.
Boston Scientific Corporation has received Food and Drug Administration (FDA) approval for the Innova™ Vascular Self-Expanding Stent System, an advanced treatment option for patients with narrowing or blockages in the superficial femoral artery (SFA) or proximal popliteal artery (PPA). This can cause peripheral artery disease (PAD), a circulatory disorder that results from a build-up of plaque in one or more of the arteries, most often in the legs. PAD of the lower extremities can lead to painful ulcers, infections, or amputation of the toes or feet. The company has commenced a full commercial launch of the Innova Stent System in the U.S.
“It is gratifying to be able to offer this minimally invasive therapy to improve the quality of life in those patients who suffer from PAD,” said Richard Powell, M.D., section chief, Department of Vascular Surgery, Dartmouth Hitchcock Medical Center, Lebanon, N.H., professor of Surgery and Radiology at the Geisel School of Medicine, and global principal investigator of the SuperNOVA trial, evaluating the safety and effectiveness of the Innova Stent System. “The SFA and proximal popliteal arteries present a challenging environment for stents. The flexibility, radial strength and fracture resistance of the Innova Stent are designed specifically for this anatomy.”
The Innova stent platform comprises of a Nitinol self-expanding bare metal stent with an advanced delivery system, and is accessible in a range of sizes, counting diameters from 5 mm to 8 mm and lengths of 20 mm to 200 mm. It features a hybrid cell architecture with open-cells along the stent body and closed cells at each end for uniform and accurate deployment. This stent platform serves as the foundation for the new Eluvia™ Drug-Eluting Vascular Stent, designed specifically for the SFA. The Innova Stent System was designed with an intuitive triaxial delivery system for precise, predictable stent placement and uniform deployment.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
